KIR2DL1 and acute lymphoblastic leukemia: Overall, we observed that NKG2C+ KIR2DL2/3− CD57− NK cell subsets (and probably KIR2DL1+), amplified in C2+ CMV+ individuals, were the most effective subsets against ALL H9 and primary cells, as well as against primary AML targets.